By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
-
Patent number: 10227651Abstract: We have identified a suite of genes in a limited number of human colonic tissue samples with expression patterns that correlate with whether an individual is experiencing symptoms of Irritable Bowel Syndrome (IBS) (FIG. 2). Interestingly, in the efforts to screen for genes that might be used as biomarkers for IBS, it was found that no single gene could be used for this purpose. Instead, when examining the entire dataset, there exist signature gene expression patterns (e.g., fingerprints or biosignatures) of IBS that have use as a diagnostic tool for IBS.Type: GrantFiled: February 24, 2015Date of Patent: March 12, 2019Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Todd Sandrin, Peter Jurutka
-
Patent number: 10221461Abstract: Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged DNA (and/or subsequently transcribed RNA) sequences encoding T cell receptor (TCR) and/or immunoglobulin (IG) polypeptides, in a lymphoid DNA-containing sample from the subject TCR and/or IG sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of T cell or B cell clonality and clerical expansion in the sample. Methods for stratifying patient populations on the basis of immunocompetence including likelihood of responding to immunotherapy are also described.Type: GrantFiled: June 29, 2017Date of Patent: March 5, 2019Assignees: ADAPTIVE BIOTECHNOLOGIES CORP., MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Harlan S. Robins, Julie Rubinstein, Ryan Emerson, Jianda Yuan
-
Patent number: 10221447Abstract: The present invention is directed to methods for identifying the presence of one or more methylated or unmethylated target nucleotide sequences in a sample that involve coupled methylation sensitive restriction enzyme digestion-ligation and/or extension processes. In some embodiments, the ligation and primary extension products formed in the reaction processes of the present invention are subsequently amplified using a polymerase chain reaction. The ligation products or primary extension products are detected, and the presence of one or more methylated or unmethylated target nucleotide sequences in the sample is identified based on the detection.Type: GrantFiled: March 31, 2015Date of Patent: March 5, 2019Assignee: Cornell UniversityInventor: Francis Barany
-
Patent number: 10208355Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.Type: GrantFiled: November 8, 2016Date of Patent: February 19, 2019Assignee: Genentech, Inc.Inventors: Carlos Bais, Richard Bourgon, Thomas Sandmann
-
Patent number: 10208356Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).Type: GrantFiled: October 16, 2018Date of Patent: February 19, 2019Assignee: Becton, Dickinson and CompanyInventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
-
Patent number: 10202651Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.Type: GrantFiled: July 17, 2017Date of Patent: February 12, 2019Assignee: Cambridge Enterprise LimitedInventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
-
Patent number: 10202631Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include as says for total bacterial growth, bacterial metabolic activity, and biofilm formation.Type: GrantFiled: March 14, 2014Date of Patent: February 12, 2019Assignees: University of Cincinnati, The United States of America as Represented by the Secretary of the Air ForceInventors: Daniel J. Hassett, Thomas J. Lamkin, Warunya Panmanee, Deborah E. Taylor, Chloe J. A. Shea
-
Patent number: 10196681Abstract: Provided herein are methods, processes and apparatuses for determining the fraction of fetal nucleic acid in a test sample derived from a pregnant female with improved accuracy and/or precision. Also, provided herein are methods, processes and apparatuses for determining the presence or absence of a genetic variation in a fetus with improved accuracy and/or precision. Certain methods include using fetal fraction measurements for the determination of a fetal genetic variation.Type: GrantFiled: March 14, 2013Date of Patent: February 5, 2019Assignee: Sequenom, Inc.Inventors: Cosmin Deciu, Zeljko Dzakula, John Allen Tynan, Grant Hogg
-
Patent number: 10196678Abstract: Embodiments provide detection systems and methods for detecting the presence of a nucleic acid in one or more samples. In a detection method, a sample and one or more nucleic acid probes are introduced into a channel. A first potential difference is applied across the length of the channel in a first direction, and a first electrical property value is detected. Subsequently, a second potential difference is applied across the length of the channel in a second opposite direction, and a second electrical property value is detected. Presence or absence of a nucleic acid in the channel is determined based on a comparison between the first and second electrical property values.Type: GrantFiled: November 7, 2014Date of Patent: February 5, 2019Assignees: ALVEO Technologies Inc., The Regents of the University of CaliforniaInventors: Sumita Pennathur, Peter Joseph Crisalli, Ronald Phillip Chiarello
-
Patent number: 10196697Abstract: A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.Type: GrantFiled: December 12, 2014Date of Patent: February 5, 2019Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Steven Walker, Andrena McCavigan, Timothy Davison, Richard Kennedy, Paul Harkin, Laura Hill
-
Patent number: 10190121Abstract: The invention relates to novel aptamers, in particular aptamers which are capable of binding to EGFR. The invention also relates to cancer cell binding complexes comprising said aptamers and the use of said cancer cell binding complexes in the treatment of cancer.Type: GrantFiled: June 23, 2015Date of Patent: January 29, 2019Assignee: Avvinity Therapeutics LimitedInventors: Bradley Hall, Paul Hatala
-
Patent number: 10190160Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.Type: GrantFiled: August 22, 2014Date of Patent: January 29, 2019Assignees: Children's Medical Center Corporation, The Technical University of Denmark, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.Inventors: Zoltan Szallasi, Nicolai Juul Birkbak, Aron Eklund, Daniel Silver, Zhigang Wang, Andrea Richardson
-
Patent number: 10186332Abstract: A determination device for enabling a computer to carry out a process including the steps of: obtaining an analysis result on methylation status of a CpG site located in a promoter region of at least one gene selected from HOXB4 (Homeobox B4) and ZSCAN31 (zinc finger and SCAN domain containing 31) in a DNA sample derived from a subject; and outputting a determination result as information on lung cancer in the subject based on the resulting analysis result is provided. A computer readable medium and a marker for obtaining information on lung cancer are also provided.Type: GrantFiled: July 9, 2015Date of Patent: January 22, 2019Assignees: SYSMEX CORPORATION, THE UNIVERSITY OF TOKYOInventors: Kaya Tai, Genta Nagae, Hiroyuki Aburatani
-
Patent number: 10184944Abstract: The present invention relates to a method for detecting molecules.Type: GrantFiled: March 11, 2014Date of Patent: January 22, 2019Assignee: The Francis Crick Institute LimitedInventors: Banafshe Larijani, Peter Parker, Selvaraju Veeriah
-
Patent number: 10184939Abstract: The present disclosure provides a method of identifying a peptide antigen, including contacting an antibody-comprising composition to a peptide microarray having an array surface and a plurality of feature pairs disposed thereon. Each of the feature pairs includes a first feature of wild-type peptides having a defined sequence and a second feature of mutant peptides having the defined sequence with a single amino acid mutation. Each of the wild-type peptides and the mutant peptides has an array-coupled terminus coupled to the array surface and an opposing free terminus, and the position of the amino acid mutation in the mutant peptides is located closer to the array-coupled terminus of the mutant peptides than the free terminus. The method further includes detecting binding of an antibody in the antibody-comprising composition to at least one of the feature pairs on the peptide microarray, and identifying feature pairs exhibiting differential binding.Type: GrantFiled: February 3, 2017Date of Patent: January 22, 2019Assignee: ROCHE SEQUENCING SOLUTIONS, INC.Inventors: Ryan Bannen, Jigar Patel, Ken Lo
-
Patent number: 10174367Abstract: The present disclosure provides methods, devices and systems that enable simultaneous multiplexing amplification reaction and real-time detection in a single reaction chamber.Type: GrantFiled: October 12, 2016Date of Patent: January 8, 2019Assignee: INSILIXA, INC.Inventors: Arjang Hassibi, Kshama Jirage, Arun Manickam, Rituraj Singh
-
Patent number: 10174314Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA-323, miRNA-342, miRNA-326, miRNA-371, miRNA-3157 and/or miRNA-345 molecule, an equivalent or a source thereof in a disease and condition associated with a squamous cell carcinoma such as head and neck cancer or a preneoplastic mucosal change.Type: GrantFiled: December 20, 2012Date of Patent: January 8, 2019Assignees: INTERNA TECHNOLOGIES B.V., VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORGInventors: Rudolf Henrikus Brakenhoff, Marlon Van Der Plas, Sanne Rosaly De Kemp, Willemijn Maria Gommans, Grégoire Pierre André Prevost, Roeland Quirinus Jozef Schaapveld, Francesco Cerisoli
-
Patent number: 10169640Abstract: A method for fingerprint identification and a terminal are provided. The method includes the follows. Source fingerprint data for fingerprint identification is acquired. Fingerprint data to be processed, whose fingerprint data value in a preset threshold range, is extracted from the source fingerprint data. A feature amplifying process is performed on the fingerprint data to be processed and the fingerprint data amplified is repaired to obtain repaired target fingerprint data. A three-dimensional surface is generated according to capacitance values of pixels of the target fingerprint data, a fingerprint image is simulated via the three-dimensional surface, and the simulated fingerprint image is compared with pre-stored fingerprint verification data. The source fingerprint data is determined to be identified successfully, based on a determination that the simulated fingerprint image matches the pre-stored fingerprint verification data.Type: GrantFiled: May 24, 2018Date of Patent: January 1, 2019Assignee: Guangdong Oppo Mobile Telecommunications Corp., Ltd.Inventor: Yibao Zhou
-
Patent number: 10168336Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.Type: GrantFiled: August 24, 2016Date of Patent: January 1, 2019Assignee: Ventana Medical Systems, Inc.Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
-
Patent number: 10168342Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.Type: GrantFiled: March 25, 2016Date of Patent: January 1, 2019Assignee: The Scripps Research InstituteInventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
-
Patent number: 10167504Abstract: The present invention provides a method of sequencing a polynucleotide using a stepwise ligation and cleavage method in which two or more cleavage enzymes which are specific to two or more test probes are used sequentially to identify which test probe bound and hence the sequence of the target polynucleotide. In a preferred aspect the probes and/or bases used in the reaction are labelled, e.g. with a bead.Type: GrantFiled: September 30, 2011Date of Patent: January 1, 2019Assignee: GENESEQUE ASInventor: Jarle Kotsbak
-
Patent number: 10155801Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: July 24, 2018Date of Patent: December 18, 2018Assignee: IMMATICS BIOTECHNOLOGY GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Patent number: 10151003Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).Type: GrantFiled: July 18, 2018Date of Patent: December 11, 2018Assignee: Cellular Research, Inc.Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
-
Patent number: 10151760Abstract: The present disclosure relates to a method for validating an existence of a urinary exosome including steps as follows. A urine sample is obtained from a subject. The urine sample is performing a serially centrifugation step to obtain a third precipitate. The third precipitate is resuspended with an extraction solvent to obtain a third mixture, and the third mixture is centrifuged to obtain a fourth supernatant. The fourth supernatant is analyzed by a mass spectrometry to detect whether there is a particular peptide therein.Type: GrantFiled: November 4, 2016Date of Patent: December 11, 2018Assignee: CHINA MEDICAL UNIVERSITYInventor: Shih-Yi Lin
-
Patent number: 10131958Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).Type: GrantFiled: July 18, 2018Date of Patent: November 20, 2018Assignee: Cellular Research, Inc.Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
-
Patent number: 10118963Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.Type: GrantFiled: January 27, 2017Date of Patent: November 6, 2018Assignee: Sorrento Therapeutics, Inc.Inventor: Heyue Zhou
-
Patent number: 10118947Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.Type: GrantFiled: April 11, 2014Date of Patent: November 6, 2018Assignee: BicycleRD LimitedInventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
-
Patent number: 10106847Abstract: The present disclosure relates to methods and devices for amplifying a plurality of targets in a single PCR run while distinguishing between clinically relevant amplification and amplification from other sources such as from background contamination. The methods and devices further enable discrimination between gram-positive, gram-negative and fungal infections as wells as identify antimicrobial resistance genes. When applying the methods and devices of the invention, the species or genus of an infection(s), and genus of a fungal co-infection(s) or category of bacterial (gram-positive or negative) co-infection(s) are identified. Species identification of co-infections can also be achieved. Further, when applying the methods and devices of the invention, organisms which are likely to be contaminating organisms from a blood draw are identified.Type: GrantFiled: November 30, 2017Date of Patent: October 23, 2018Assignee: Clinical Micro Sensors, Inc.Inventors: Bradley Adam Brown, Milena Iacobelli Martinez, Lisa Lynn Freeman-Cook, John Jay Harvey, Christine J. Shaw, Anna Maria Al-Khouri
-
Patent number: 10101249Abstract: An object of the present invention is to provide: a staining agent for tissue staining which has an improved fluorescence signal evaluation accuracy; and a tissue staining kit comprising the staining agent. The staining agent for tissue staining contains, as a staining component, dye-resin particles comprising thermosetting resin particles and a fluorescent dye immobilized on the resin particles, wherein the resin particles contains a substituent having an electric charge opposite to that of the fluorescent dye and forms an ionic bond or a covalent bond with the fluorescent dye, and the dye-resin particles have a particle size variation coefficient of 15% or less.Type: GrantFiled: January 9, 2018Date of Patent: October 16, 2018Assignee: Konica Minolta, Inc.Inventors: Kensaku Takanashi, Yasushi Nakano, Takeshi Isoda, Hideki Gouda
-
Patent number: 10093922Abstract: The present invention provides compositions comprising randomized in-frame fusion polynucleotides and methods for introducing them into a host organism to identify desirable phenotypic changes that disrupt or alter existing genetic or biochemical mechanisms or pathways, thus creating novel characteristics of the transformed organism. Methods for using the compositions for increasing diversity within populations of organisms are also presented.Type: GrantFiled: December 19, 2013Date of Patent: October 9, 2018Inventor: Helge Zieler
-
Patent number: 10093977Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.Type: GrantFiled: February 28, 2008Date of Patent: October 9, 2018Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 10088482Abstract: The present invention relates to a method of aiding in the prognosis of a subject with oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma, the method comprising the steps of: (a) providing a sample from the subject, (b) determining the expression level of biomarkers TRIM44 and SIRT2 in said sample, and either (i) determining the expression level of biomarker PAPPS2 in said sample; or (ii) determining the expression level of biomarkers WT1 and EGFR in said sample; (c) comparing the expression level of each of said biomarkers to a corresponding reference standard, (d) determining the biomarkers of (b) whose expression is dysregulated compared to the reference standard, (e) inferring from the dysregulated biomarkers identified in (d) the prognosis of 5-year survival, wherein the greater the number of said biomarkers which are dysregulated, the greater the reduction in prognosis of 5-year survival. The invention also relates to kits, uses and devices.Type: GrantFiled: October 7, 2016Date of Patent: October 2, 2018Assignees: Cambridge Enterprise Limited, United Kingdom Research and InnovationInventors: Christopher J. Peters, Carlos Caldas, Rebecca C. Fitzgerald
-
Patent number: 10090472Abstract: A method of fractionating a semiconducting polymer wherein the semiconducting polymer comprises polymer chains comprising a defect group, the method comprising the steps of reacting the polymer chains comprising a defect group to form polymer chains comprising separating groups; and separating the polymer chains comprising the separating groups from the semiconducting polymer. The separating group may be a binding group X capable of binding to a solid substrate material 305, for example particulate silica.Type: GrantFiled: December 14, 2015Date of Patent: October 2, 2018Assignees: Cambridge Display Technology Limited, Sumitomo Chemical Company LimitedInventor: Jonathan Pillow
-
Patent number: 10081807Abstract: Methods and compositions relate to the sorting and cloning of high fidelity nucleic acids using high throughput sequencing. Specifically, nucleic acid molecules having the desired predetermined sequence can be sorted from a pool comprising a plurality of nucleic acids having correct and incorrect sequences.Type: GrantFiled: April 24, 2013Date of Patent: September 25, 2018Assignee: Gen9, Inc.Inventors: Joseph Jacobson, Martin J. Goldberg, Li-yun A. Kung, Daniel Schindler, Michael E. Hudson
-
Patent number: 10071358Abstract: Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.Type: GrantFiled: December 10, 2012Date of Patent: September 11, 2018Assignee: PROTEIN DESIGN LAB, LTD.Inventor: Xiaoqing Qiu
-
Patent number: 10072303Abstract: This document provides methods and materials for treating endometrial cancer. For example, methods and materials for identifying a female mammal as having endometrial cancer and surgically removing at least the uterus of the female are provided.Type: GrantFiled: March 27, 2015Date of Patent: September 11, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Andrea Mariani, Nicholas Chia, Marina R. Walther-Antonio
-
Patent number: 10059742Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.Type: GrantFiled: July 20, 2016Date of Patent: August 28, 2018Assignee: The Governing Council of the University of TorontoInventor: Paulo Koeberle
-
Patent number: 10053484Abstract: The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.Type: GrantFiled: December 12, 2016Date of Patent: August 21, 2018Assignee: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
-
Patent number: 10047396Abstract: The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA).Type: GrantFiled: February 14, 2016Date of Patent: August 14, 2018Assignee: The Regents of the University of CaliforniaInventors: Frank Sharp, Xinhua Zhan, Glen C. Jickling, S. Claiborne Johnston
-
Patent number: 10041934Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: GrantFiled: June 24, 2016Date of Patent: August 7, 2018Assignee: Celcuity LLCInventors: Lance Gavin Laing, Brian Francis Sullivan
-
Patent number: 10040992Abstract: Chemiluminesescence is emitted from a reaction between phenylglyoxal derivatives and guanine. This chemiluminescence can be used in CRET for the detection of one or more analytes of interest. Chemical pathways depicting the chemiluminescent reaction and intermediates produced therein are shown, as are novel nanoparticles for use in the present methods and compositions.Type: GrantFiled: May 9, 2014Date of Patent: August 7, 2018Assignee: LUMINESCENT MD, LLCInventors: Ji Hoon Lee, Sandy Cho
-
Patent number: 10036068Abstract: Methods are provided for diagnosis, prognosis, and treatment associated with a cardiovascular event in a subject as well as methods of providing anti-platelet therapy. The methods can comprise obtaining a sample from the subject, and determining the presence of at least two single nucleotide polymorphisms (SNP) in the sample selected from Rs7541936 in PTGER3, Rs977214 in PTGER3, and Rs2206343 in PTGER3. The methods can also comprise determining the presence in the sample of Rs4383756 in PTGER4. Some methods comprise administering conventional anti-platelet therapy to the subject if Rs4383756 in PTGER4 is present in the sample. Furthermore, some methods comprise administering an EP3 antagonist and/or conventional anti-platelet therapy to the subject if Rs4383756 in PTGER4 is not present in the sample. The cardiovascular event can involve thrombosis or an embolic event, a myocardial infarction, a stroke, a primary cardiovascular event, or coronary artery disease.Type: GrantFiled: July 8, 2013Date of Patent: July 31, 2018Assignee: Vanderbilt UniversityInventors: Olivier Boutaud, Elias Haddad
-
Patent number: 10030263Abstract: Described herein are multiplexed RNA, including miRNA, PCR-based assays.Type: GrantFiled: August 24, 2015Date of Patent: July 24, 2018Assignee: University of South FloridaInventors: Jia-Wang Wang, Richard F. Lockey
-
Patent number: 10024859Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be differentially expressed in gastric tumor tissue, and thus can be used as markers for the detection of gastric and other types of cancer. The present invention provides for novel GTMs for the detection of tumors, including gastric tumors, and in particular human zymogen granule protein 16 (ZG16). The GTMs can be used in isolation or together with other known GTMs to provide for novel signatures to be used in the detection of tumors, including gastric tumors.Type: GrantFiled: April 12, 2016Date of Patent: July 17, 2018Assignee: PACIFIC EDGE LIMITEDInventor: Parry John Guilford
-
Patent number: 10011880Abstract: MicroRNAs are provided for evaluating the physiological and/or pathological condition of a subject; and a kit thereof is provided for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors.Type: GrantFiled: June 2, 2016Date of Patent: July 3, 2018Assignee: JIANGSU MINGMA BIOTECH CO., LTD.Inventors: Chenyu Zhang, Junfeng Zhang, Xi Chen, Yi Ba, Jiangning Chen, Jin Wang, Ke Zeng, Hongjie Zhang
-
Patent number: 10011870Abstract: The present disclosure provides methods and compositions for sequencing nucleic acid molecules and identifying individual sample nucleic acid molecules using Molecular Index Tags (MITs). Furthermore, reaction mixtures, kits, and adapter libraries are provided.Type: GrantFiled: December 7, 2016Date of Patent: July 3, 2018Assignee: Natera, Inc.Inventors: Bernhard Zimmermann, Ryan Swenerton, Matthew Rabinowitz, Styrmir Sigurjonsson, George Gemelos, Apratim Ganguly, Himanshu Sethi
-
Patent number: 10005080Abstract: In one embodiment, a multiplex fluid processing cartridge includes a sample well, a deformable fluid chamber, a mixing well with a mixer disposed therein, a lysis chamber including a lysis mixer, an electrowetting grid for microdroplet manipulation, and electrosensor arrays configured to detect analytes of interest. An instrument for processing the cartridge is configured to receive the cartridge and to selectively apply thermal energy, magnetic force, and electrical connections to one or more discrete locations on the cartridge and is further configured to compress the deformable chamber(s) in a specified sequence.Type: GrantFiled: November 11, 2014Date of Patent: June 26, 2018Assignees: GENMARK DIAGNOSTICS, INC., ADVANCED LIQUID LOGIC, INC.Inventors: Jon Faiz Kayyem, Sean Ford, Vamsee K. Pamula, Vijay Srinivasan, Scott Corey, Brian Murphy, David Walter Wright, Dominic Aiello
-
Patent number: 10002316Abstract: The disclosure provides for methods, compositions, systems, devices, and kits for determining the number of distinct targets in distinct spatial locations within a sample. In some examples, the methods include: stochastically barcoding the plurality of targets in the sample using a plurality of stochastic barcodes, wherein each of the plurality of stochastic barcodes comprises a spatial label and a molecular label; estimating the number of each of the plurality of targets using the molecular label; and identifying the spatial location of each of the plurality of targets using the spatial label. The method can be multiplexed.Type: GrantFiled: August 2, 2017Date of Patent: June 19, 2018Assignee: Cellular Research, Inc.Inventors: Stephen P. A. Fodor, Christina Fan, Glenn Fu, Geoffrey Facer
-
Patent number: 10000732Abstract: A microfluidic dual-well device is disclosed. The device comprises: (a) a first substrate having a first end, a second end, and a culture microwell forming portion; (b) a plurality of culture microwells; (c) a second substrate having a first end, a second end, and a capture microwell forming portion, the two ends of the second substrate being respectively bounded to the two ends of the first substrate; (d) a plurality of capture microwells; (e) a microfluidic channel; (f) a microfluidic inlet port; and (g) a microfluidic outlet port; wherein the microfluidic channel is in fluidic connections with the culture microwells, the capture microwells, and the inlet and outlet ports. Methods of capturing and transferring a single cell or a single cell colony for culture, and method of transferring a target cell from a polydimethylsiloxane (PDMS) structure of culture microwells to a culture plate for culture are also disclosed.Type: GrantFiled: May 19, 2016Date of Patent: June 19, 2018Assignee: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Chia-Hsien Hsu, Ching-Hui Lin, Hao-Chen Chang, Ing-Ming Chiu
-
Patent number: 9994617Abstract: The invention describes a method for selecting a polypeptide ligand having a desired level of specificity for a target, wherein the polypeptide ligand comprises a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, comprising (i) screening at least two different sets of polypeptide ligands against the target, and selecting one or more ligands from each library which interact with the target; (ii) comparing the activity of the selected ligands with one or more paralogues or orthologues of the target; and (iii) further selecting one or more ligands according to their activity towards said one or more paralogues or orthologues; wherein said two or more different sets of ligands differ in the length of the polypeptide loops formed on the molecular scaffold.Type: GrantFiled: October 8, 2012Date of Patent: June 12, 2018Assignee: BicycleRD LimitedInventors: John Tite, Edward Walker, Catherine Stace, Christian Heinis